Ironwood Pharmaceuticals Inc. Overview

Ironwood Pharmaceuticals, Inc., a prominent player in the biotechnology sector, is headquartered in Boston, Massachusetts. The company is dedicated to the discovery, development, manufacturing, and commercialization of pharmaceuticals aimed at treating a range of conditions, including cholesterol, gastrointestinal, cardiovascular diseases, pain, inflammation, and other health issues. For more detailed information about their products and initiatives, interested parties can visit their official website at www.ironwoodpharma.com .

Recent Stock Performance

As of May 8, 2025, Ironwood Pharmaceuticals’ stock closed at $0.7092 on the Nasdaq exchange. This figure represents a significant fluctuation over the past year, with the stock reaching a 52-week high of $7.105 on July 25, 2024, and a 52-week low of $0.591 on April 13, 2025. The company’s market capitalization currently stands at approximately $147.55 million.

Financial Metrics

The company’s financial metrics reveal a price-to-earnings (P/E) ratio of 62.228, indicating the market’s valuation of the company relative to its earnings. This high P/E ratio suggests that investors may have high expectations for future growth, despite the recent volatility in stock price.

Industry and Sector

Ironwood Pharmaceuticals operates within the health care sector, specifically focusing on biotechnology. This industry is characterized by its emphasis on innovation and the development of new medical treatments and technologies.

For further updates and detailed insights into Ironwood Pharmaceuticals’ operations and financial health, stakeholders are encouraged to monitor their official communications and financial disclosures.